Supporting Information

DBS Assay with LC-MS/MS for the Determination of Idelalisib, A Selective PI3K-δ Inhibitor in Mice Blood and Its Application to a Pharmacokinetic Study

Authors

Harsha K. Tripathy[1], Nair S.V. Manju[1], Sreekanth Dittakavi[2], Ashok Zakkula[2], Ramesh Mullangi[2]

Affiliations

1 Karnataka College of Pharmacy, Thirumenahalli, Bangalore, India
2 Drug Metabolism and Pharmacokinetics, Jubilant Biosys Ltd, Industrial Suburb, Yeshwanthpur, Bangalore, India

Correspondence

Dr. Ramesh Mullangi
Drug Metabolism and Pharmacokinetics,
Jubilant Biosys Ltd,
Industrial Suburb, Yeshwanthpur,
Bangalore-560 022
India
Tel.: + 91-80-66628339, Fax: + 91-80-66628333
mullangi.ramesh@jubilantinnovation.com

Supplementary Table 1S. Summary of published LC-MS/MS and HPLC assay methods for idelalisib quantitation in various biological matrices

Parameters								Reference
Linearity range (ng/mL)	**Plasma volume (µL)**	**Total run time (min)**	**Column/ injection volume**	**Recovery (%)**	**Extraction technique/ Internal standard**	**Ionization/ acquisition mode**	**Application**	
1.15-576	50	4.00	YMC-PACK ODS C_{18}/5 µL	84-87	LLE/ tolbutamide	ESI/SRM	PK study in rats	[6]
20-4000	250	10.0	ODS C_{18}/ 10 µL	81-91	PPT/ibrutinib	HPLC	PK study in rabbits	[7]
10-2500	50	3.00	UPLC BEH C_{18}/ 5 µL	84-86	PPT/[$^2H_5$]-idelalisib	ESI/SRM	In cancer patients	[8]
0.10-600	50	3.00	UPLC BEH C_{18}/2 µL	85-92	LLE/[$^2H_5$]-idelalisib	ESI/SRM	PK study in dogs	[9]
70-7017	NA	NA	NA	NA	SPE/NA	NA	BE study in healthy humans	[10]
1.01-4797	10*	2.00	Atlantis dC_{18}/ 2 µL	67-69	LLE/ larotrectinib	ESI/MRM	PK study in mice	Present method

*: matrix is blood; BE: bioequivalence; ESI: electro-spray ionization; LLE: liquid-liquid extraction; MRM: multiple reaction monitoring; NA: not available; PK: pharmacokinetic; PPT: protein precipitation; SPE: solid phase extraction; SRM: selective reaction monitoring.